Mas de 100 patentes expiraran a lo largo de 2009. Entre ellas se incluyen 13 grandes productos. Las compañias más afectadas serán GlaxoSmithKline y Pfizer seguidas de Novartis y Takeda.
En el 2008 fueron Merck & Co's Fosamax (alendronate), Pfizer's Camptosar (irinotecan) and Wyeth's Effexor XR (venlafaxine).
Según previsiones de Global Insight:
...a number of distinctive trends began to emerge last year in the patent challenge arena.
- First was the relative confidence among generics makers to challenge much earlier in the patent lifecycle than was previously the case.
- Second was their focus on niche therapeutic areas with restricted high-margin product markets - generics giants including Teva Pharma, Ranbaxy, Stada and Mylan were actively pursuing this trend.
- And third was Big Pharma’s willingness to accept settlements with generis makers again much earlier in the patent lawsuit period.
Entradas
No hay comentarios:
Publicar un comentario